First-in-class programs
Pipeline
| Program | Track | Indication | Modality | Stage | Next milestone |
|---|---|---|---|---|---|
| aFMT-102 | CNS | Major depressive disorder & mood disorders | Live biotherapeutic (Bifidobacterium longum strain) / FMT 3.0 | Preclinical | IND-enabling studies |
| ICI-sensitizing FMT (CRC) | Onco | pMMR / MSS colorectal cancer (ICI-refractory) | FMT 3.0 + immune-checkpoint inhibitor combination | Discovery | Investigator-led cohort expansion |
Stages are reported conservatively and reflect current development status; entries are backed by the evidence referenced on each program and on the Evidence pages. This is not a statement of regulatory approval or a guarantee of clinical outcome.